MyoScience has named aesthetic industry veteran and Solta Medical previous COO Clint Carnell as president and CEO, effective 1 April 2011.
Prior to Solta Medical, Carnell served as VP of Sales for the Surgical Division of Bausch & Lomb.
MyoScience chairman and DeNovo Ventures MD Rich Ferrari said Clint has relationships with key influencers in aesthetics, a demonstrated track record of scaling companies for success and a reputation for leadership that will be critical as they position the company for commercial launch.
MyoScience is developing an innovative medical device and minimally invasive procedure to deliver a precisely controlled subcutaneous cooling effect to relax facial muscles that cause dynamic facial wrinkles to form.
The patented CRYNEUROMODULATION procedure would be expected to offer specialty aesthetic physicians a new procedure for the very large group of patients who prefer a new neurotoxin-free alternative to BOTOX Cosmetic, Dysport, or other brands of neurotoxin compounds.
The MyoScience CRYONEUROMODULATION technology, cleared by the US FDA for general surgical use and for the treatment of peripheral nerves for relieving pain, is currently in clinical trials for reducing dynamic facial wrinkles (such as frown lines between the brows, forehead lines, and crow’s feet) in the upper face.